Abstract | BACKGROUND: OBJECTIVES: To investigate whether modulation of inflammatory activity by tumour necrosis factor-α inhibitors in patients with psoriasis is associated with modification of lipid profiles, oxidative stress and paraoxonase (PON)1 activity. METHODS: RESULTS: The results showed that clinical improvement in patients with psoriasis treated with etanercept is associated with a reduction in the levels of inflammatory markers [ C-reactive protein (CRP)] and lipid peroxidation, and also with increased antioxidant capacity in the serum of patients with psoriasis. These modifications are associated with a significant increase in the activity of PON1. A significant increase in the PON1/CRP ratio has also been observed in patients with psoriasis after treatment. The significant inverse correlation between CRP and PON1 activity suggests a relationship between PON1 activity and inflammation. CONCLUSIONS: Treatment with etanercept is associated with a reduction in lipid peroxidation and an improvement in HDL antioxidant and anti-inflammatory properties.
|
Authors | T Bacchetti, A Campanati, G Ferretti, O Simonetti, G Liberati, A M Offidani |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 168
Issue 5
Pg. 984-9
(May 2013)
ISSN: 1365-2133 [Electronic] England |
PMID | 23614561
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | © 2013 The Authors. BJD © 2012 British Association of Dermatologists. |
Chemical References |
- Biomarkers
- Immunoglobulin G
- Immunosuppressive Agents
- Lipids
- Lipoprotein(a)
- Lipoproteins, HDL
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- C-Reactive Protein
- Aryldialkylphosphatase
- PON1 protein, human
- Etanercept
|
Topics |
- Adult
- Aryldialkylphosphatase
(metabolism)
- Biomarkers
(metabolism)
- C-Reactive Protein
(metabolism)
- Etanercept
- Female
- Humans
- Immunoglobulin G
(therapeutic use)
- Immunosuppressive Agents
(therapeutic use)
- Lipid Peroxidation
(drug effects)
- Lipids
(blood)
- Lipoprotein(a)
(blood)
- Lipoproteins, HDL
(metabolism)
- Male
- Middle Aged
- Oxidation-Reduction
(drug effects)
- Oxidative Stress
(drug effects)
- Psoriasis
(blood, drug therapy)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Severity of Illness Index
- Time Factors
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|